PureTech Health PLC (PRTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PureTech Health PLC (PRTC) has a cash flow conversion efficiency ratio of -0.126x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.34 Million) by net assets ($369.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PureTech Health PLC - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how PureTech Health PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of PureTech Health PLC for a breakdown of total debt and financial obligations.
PureTech Health PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PureTech Health PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yibin Paper Industry Co Ltd
SHG:600793
|
0.088x |
|
Logan Energy Corp
V:LGN
|
0.019x |
|
Lontrue Co Ltd
SHE:300175
|
-0.107x |
|
AS Tallink Grupp
HE:TALLINK
|
0.086x |
|
Sofwave Medical Ltd
TA:SOFW
|
0.097x |
|
Paysafe Ltd
NYSE:PSFE
|
0.114x |
|
LH Hotel Leasehold Real Estate Investment Trust
BK:LHHOTEL
|
0.032x |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
0.051x |
Annual Cash Flow Conversion Efficiency for PureTech Health PLC (2012–2024)
The table below shows the annual cash flow conversion efficiency of PureTech Health PLC from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of PureTech Health PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $407.93 Million | $-134.37 Million | -0.329x | -42.50% |
| 2023-12-31 | $458.23 Million | $-105.92 Million | -0.231x | +29.21% |
| 2022-12-31 | $547.59 Million | $-178.79 Million | -0.327x | -20.51% |
| 2021-12-31 | $584.15 Million | $-158.27 Million | -0.271x | -34.32% |
| 2020-12-31 | $653.54 Million | $-131.83 Million | -0.202x | -33.66% |
| 2019-12-31 | $650.40 Million | $-98.16 Million | -0.151x | +65.38% |
| 2018-12-31 | $166.97 Million | $-72.80 Million | -0.436x | +68.54% |
| 2017-12-31 | $64.00 Million | $-88.69 Million | -1.386x | -120.68% |
| 2016-12-31 | $92.41 Million | $-58.03 Million | -0.628x | -260.08% |
| 2015-12-31 | $164.05 Million | $-28.61 Million | -0.174x | -121.14% |
| 2014-12-31 | $133.69 Million | $-10.54 Million | -0.079x | -107.21% |
| 2013-12-31 | $-8.03 Million | $-8.77 Million | 1.093x | +152.49% |
| 2012-12-31 | $-3.35 Million | $-1.45 Million | 0.433x | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more